The Antipsychotic Medication Management Fidelity Scale: Psychometric properties

Torleif Ruud, Karin Drivenes, Robert E Drake, Vegard Øksendal Haaland, Matthew Landers, Bjørn Stensrud, Kristin S Heiervang, Lars Tanum, Gary R Bond, Torleif Ruud, Karin Drivenes, Robert E Drake, Vegard Øksendal Haaland, Matthew Landers, Bjørn Stensrud, Kristin S Heiervang, Lars Tanum, Gary R Bond

Abstract

The paper describes the Antipsychotic Medication Management Fidelity Scale and its psychometric properties, including interrater reliability, frequency distribution, sensitivity to change and feasibility. Fidelity assessors conducted fidelity reviews four times over 18 months at eight sites receiving implementation support for evidence-based antipsychotic medication management. Data analyses shows good to fair interrater reliability, adequate sensitivity to change over time and good feasibility. At 18 months, item ratings varied from poor to full fidelity on most items. Use of the scale can assess fidelity to evidence-based guidelines for antipsychotic medication management and guide efforts to improve practice. Further research should improve and better calibrate some items, and improve the procedures for access to information.Trial registration: ClinicalTrials.gov Identifier: NCT03271242.

Keywords: Antipsychotic medication; Evidence-based practice; Fidelity scale; Implementation; Psychosis.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Previous presentation: data have not been previously published and is not being submitted for publication elsewhere.

Figures

Fig. 1
Fig. 1
Development of fidelity overall and at policies and prescriber practices level

References

    1. Alhewiti A. Adherence to long-term therapies and beliefs about medications. International Journal of Family Medicine. 2014;2014:479596. doi: 10.1155/2014/479596.
    1. Barbui, C., Girlanda, F., Ay, E., Cipriani, A., Becker, T., & Koesters, M. (2014). Implementation of treatment guidelines for specialist mental health care. Cochrane Database of Systematic Reviews, (1), Cd009780. 10.1002/14651858.CD009780.pub2.
    1. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R. Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophrenia Research. 2011;132(1):42–49. doi: 10.1016/j.schres.2011.07.019.
    1. Beitinger R, Kissling W, Hamann J. Trends and perspectives of shared decision-making in schizophrenia and related disorders. Current Opinion in Psychiatry. 2014;27(3):222–229. doi: 10.1097/YCO.0000000000000057.
    1. Bond GR, Drake RE. Assessing the fidelity of evidence-based practices: History and current status of a standardized measurement methodology. Administration and Policy in Mental Health. 2019 doi: 10.1007/s10488-019-00991-6.
    1. Bond, G. R., Williams, J., Evans, L., Salyers, M., Kim, H. W., Sharpe, H., & Leff, H. S. (2000). Psychiatric rehabilitation fidelity toolkit. Cambridge, MA: Human Services Research Institute. .
    1. Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., …, Keller, W. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin,36(1), 71–93. 10.1093/schbul/sbp116.
    1. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: A systematic review. Patient Education and Counselling. 2012;86(1):9–18. doi: 10.1016/j.pec.2011.02.004.
    1. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment. 1994;6(4):284–290. doi: 10.1037/1040-3590.6.4.284.
    1. Crowe M, Wilson L, Inder M. Patients’ reports of the factors influencing medication adherence in bipolar disorder—An integrative review of the literature. International Journal of Nursing Studies. 2011;48(7):894–903. doi: 10.1016/j.ijnurstu.2011.03.008.
    1. De Hert, M., van Winkel, R., Silic, A., Van Eyck, D., & Peuskens, J. (2010). Physical health management in psychiatric settings. European Psychiatry, 25(2010), S22–S28, 25, 22–28.
    1. El-Mallakh P, Howard PB, Bond GR, Roque AP. Challenges of implementing a medication management evidence-based practice in a community mental health setting: Results of a qualitative study. Issues in Mental Health Nursing. 2014;35(7):517–525. doi: 10.3109/01612840.2014.888601.
    1. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety. 2012;11(4):527–542. doi: 10.1517/14740338.2012.683523.
    1. Gharabawi, G. M., Greenspan, A., Rupnow, M. F., Kosik-Gonzalez, C., Bossie, C. A., Zhu, Y., …, Awad, A. G. (2006). Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial. BMC Psychiatry,6, 45. 10.1186/1471-244x-6-45.
    1. Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., …, Aravagiri, M. (2001). Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry,158(11), 1835–1842.
    1. Goodwin, G., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., de Hert, M., …, Zohar, J. (2009). Advantages and disadvantages of combination treatment with antipsychotics. European Neuropsychopharmacology,19(7), 520–532. 10.1016/j.euroneuro.2009.04.003.
    1. Howard PB, El-Mallakh P, Miller AL, Rayens MK, Bond GR, Henderson K, Cooley AT. Prescriber fidelity to a medication management evidence-based practice in the treatment of schizophrenia. Psychiatric Services. 2009;60(7):929–935. doi: 10.1176/ps.2009.60.7.929.
    1. Iversen, T. S. J., Steen, N. E., Dieset, I., Hope, S., Morch, R., Gardsjord, E. S.,…, Jonsson, E. G. (2018). Side effect burden of antipsychotic drugs in real life—Impact of gender and polypharmacy. Progress in Neuropsychopharmacology and Biological Psychiatry,82, 263–271. 10.1016/j.pnpbp.2017.11.004.
    1. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. Journal of Chiropractic Medicine. 2016;15(2):155–163. doi: 10.1016/j.jcm.2016.02.012.
    1. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Frontiers in Psychology. 2013;4:863. doi: 10.3389/fpsyg.2013.00863.
    1. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., …, Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet,382(9896), 951–962. 10.1016/s0140-6736(13)60733-3.
    1. McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. Journal of Advanced Nursing. 2009;65(3):534–543. doi: 10.1111/j.1365-2648.2008.04906.x.
    1. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychological Methods. 1996;1:30–46. doi: 10.1037/1082-989X.1.1.30.
    1. Oosthuizen P, Emsley RA, Turner J, Keyter N. Determining the optimal dose of haloperidol in first-episode psychosis. Journal of Psychopharmacology. 2001;15(4):251–255. doi: 10.1177/026988110101500403.
    1. Rothe PH, Heres S, Leucht S. Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. Schizophrenia Research. 2018;193:23–28. doi: 10.1016/j.schres.2017.07.033.
    1. Schober P, Boer C, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. Anesthesia and Analgesia. 2018;126(5):1763–1768. doi: 10.1213/ANE.0000000000002864.
    1. Shojania KG, Grimshaw JM. Evidence-based quality improvement: The state of the science. Health Affairs. 2005;24:138–150. doi: 10.1377/hlthaff.24.1.138.
    1. Slade M. Implementing shared decision making in routine mental health care. World Psychiatry. 2017;16(2):146–153. doi: 10.1002/wps.20412.
    1. Streiner DL, Norman GR, Cairney J. Health measurement scales. A practical guide to their development and use. 5. Oxford: Oxford University Press; 2015.
    1. Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B., El-Mallakh, P., Finnerty, M., …, Miller, A. L. (2009). Scales to evaluate quality of medication management: Development and psychometric properties. Administration and Policy in Mental Health,36(4), 247–254. 10.1007/s10488-009-0209-z.
    1. van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: A systematic review. Journal of Psychopharmacology. 2015;29(8):857–866. doi: 10.1177/0269881115593893.
    1. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: Relapse rates and functional outcome. Journal of Clinical Psychiatry. 2007;68(5):654–661. doi: 10.4088/JCP.v68n0502.
    1. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Current Opinion in Psychiatry. 2010;23(2):103–111. doi: 10.1097/YCO.0b013e3283366427.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj